Table of Contents

1 Welcome from Dean Baillie  
2 Our Excellence: A Summary  
3 Grants  
4 Our Impact  
10 Our Loyal Supporters  
14 Selected Publications

Leadership

Thomas Baillie, Dean  
Peggy Odegard, Chair, Department of Pharmacy  
Allan Rettie, Chair, Department of Medicinal Chemistry  
Kenneth Thummel, Chair, Department of Pharmaceutics  
Nanci Murphy, Associate Dean, Academic & Student Programs  
Sean Sullivan, Associate Dean, Research & New Initiatives  
Stanley Weber, Associate Dean, Professional Pharmacy Education  
Claire Forster, Assistant Dean, Advancement & Corporate Relations  
Christene James, Director, Finance & Administration

Programs, Facilities and Units

Analytical Biopharmacy Core  
Community & Ambulatory Pharmacy Practice Residency Program  
DNA Sequencing & Gene Analysis Center  
Geriatric Pharmacy Program  
Institute for Innovative Pharmacy Practice  
L.D. & Jim Bracken Pharmacy Learning Center  
Mass Spectrometry Center  
Metabolism & Transport Drug Interaction Database  
Northwest-Alaska Pharmacogenomics Research Network  
Pharmaceutical Outcomes Research & Policy Program  
Pharmacokinetics Lab  
UW Obstetric-Fetal Pharmacology Research Unit  
UW Pharmacy Cares Consulting Pharmacy  
UW Research Affiliate Program on Transporters

Front Cover: Sliding doors at the entrance of the Magnuson Health Sciences Center Rotunda. Photo by Team Photogenic.
We seek to provide them with an excellent education and countless opportunities for development; then we watch them go on to successful and meaningful careers — as pharmacists, scientists, professors, public health officials, policymakers and much more.

We also take pride in the ways our students and faculty are responding to pressing needs in public health and health care. We are made up of an impassioned community of people working to improve the health and well-being of individuals and communities. This 2013 issue of “Excellence at the School of Pharmacy” is a testament to that.

Within these pages, you will find a snapshot of the work our students, faculty, alumni and volunteers are doing regionally and globally to improve health, health care and outcomes. On Page 3, for example, you will note the impressive amount of research funds our faculty members secured — for studies focused on areas including vaccine creation, drug interactions, obstetric-fetal pharmacology and comparative effectiveness research. Starting on Page 4, you can read about some students and faculty members who are having an impact — from a professor known for inspiring students in the classroom and the clinic to a graduate student helping surgeons in Tanzania improve surgical outcomes. On Page 10, we pay tribute to our generous donors and volunteers — without whom, we could not make the mark that we do.

You may notice that much of the work highlighted in this report is focused on finding safer, more-effective medicines and treatments. Part of our core mission is to help ensure the safe, rational and cost-effective use of medicines and medical products in human populations.

What a worthwhile goal this is. Better treatments lead to improved health outcomes. And that can open doors to a world of better health.

Thank you for your interest in and support of our School.

Sincerely,

Thomas A. Baillie, PhD, DSc
By the Numbers

3 The UW’s 2012 global ranking in clinical medicine and pharmacy by the Center for World-Class Universities

10 Our U.S. News & World Report 2012 ranking among schools of pharmacy

4 Number of American Association for the Advancement of Science faculty fellows in our School

42 Full-time equivalent faculty members

82 Percentage of PharmD graduates in 2012 who stayed in Washington to practice pharmacy

500+ Clinical and affiliate faculty members

466 Currently enrolled students (364 PharmD, 59 PhD, 43 MS)

$17.5 million* Overall research funding secured

$34.6 million* Revenue

*Figures are from fiscal year 2012 (July 1, 2011-June 30, 2012)

Our Stellar Programs

DEGREES:
- Doctor of Pharmacy (PharmD)
- Master of Science (MS) in Biomedical Regulatory Affairs, Pharmaceutical Outcomes Research & Policy Program (PORPP)
- Doctor of Philosophy (PhD) in Medicinal Chemistry, Pharmaceutics, PORPP
- Concurrent: PharmD/PhD, PharmD/MS, PharmD/Master of Clinical Health Services

CERTIFICATES:
- Biomedical Regulatory Affairs
- Clinical Trials
- Comparative Effectiveness Research
- Health Economics & Outcomes Research
- Plein Certificate in Geriatric Pharmacy

Revenue

1% ENDOWMENT RETURN
2% SALES & SERVICES
3% RESEARCH COST RECOVERY
3% GIFTS
11% STATE FUNDS
13% OUTPATIENT PHARMACY
13% TUITION
51% GRANTS & CONTRACTS
<table>
<thead>
<tr>
<th>Abbreviated Project Title</th>
<th>Funding Agency</th>
<th>Direct Cost Fiscal Year 2012</th>
<th>PI</th>
<th>Multiyear Total, if Applicable*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharm Optimization</td>
<td>NIH</td>
<td>$501,734</td>
<td>Anderson</td>
<td>$2,594,290</td>
</tr>
<tr>
<td>PGP Mechs</td>
<td>NIH</td>
<td>$219,000</td>
<td>Atkins</td>
<td>$880,685</td>
</tr>
<tr>
<td>LSDF Bio Center</td>
<td>WA Life Sciences Discovery Fund</td>
<td>$258,028</td>
<td>Atkins and</td>
<td>$980,778</td>
</tr>
<tr>
<td>Various Projects</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>$33,469</td>
<td>Blough</td>
<td></td>
</tr>
<tr>
<td>HIV Env Trimer Spikes</td>
<td>NIH</td>
<td>$160,232</td>
<td>Catalano</td>
<td>$273,750</td>
</tr>
<tr>
<td>Lambda Capsid</td>
<td>National Science Foundation</td>
<td>$194,382</td>
<td>Catalano</td>
<td>$717,700</td>
</tr>
<tr>
<td>Viral DNA</td>
<td>NIH (U Cal San Diego subcontract)</td>
<td>$189,706</td>
<td>Catalano</td>
<td>$348,161</td>
</tr>
<tr>
<td>Andrews F32 Fellowship</td>
<td>NIH</td>
<td>$53,942</td>
<td>Catalano</td>
<td>$152,874</td>
</tr>
<tr>
<td>CERTN EDM Paper</td>
<td>AcademyHealth/AHRQ - ARRA</td>
<td>$7,500</td>
<td>Devine</td>
<td>$134,939</td>
</tr>
<tr>
<td>Fellowship</td>
<td>Allergan Inc.</td>
<td>$75,046</td>
<td>Devine</td>
<td></td>
</tr>
<tr>
<td>Comparative Effec Rsch</td>
<td>PhRMA Foundation</td>
<td>$125,000</td>
<td>Garrison</td>
<td>$250,000</td>
</tr>
<tr>
<td>Pfizer Fellowship 3</td>
<td>Pfizer Inc.</td>
<td>$115,736</td>
<td>Garrison</td>
<td>$223,521</td>
</tr>
<tr>
<td>Bedalov Biomarkers Sub</td>
<td>NIH (FHCRC subcontract)</td>
<td>$8,123</td>
<td>Goodlett</td>
<td></td>
</tr>
<tr>
<td>Artemisinin Compounds</td>
<td>WA Life Sciences Discovery Fund</td>
<td>$87,883</td>
<td>Goodlett</td>
<td>$258,527</td>
</tr>
<tr>
<td>g2AMPK</td>
<td>NIH</td>
<td>$34,102</td>
<td>Goodlett</td>
<td>$183,787</td>
</tr>
<tr>
<td>Morrison P30 (Core B)</td>
<td>NIH</td>
<td>$175,846</td>
<td>Goodlett</td>
<td>$688,567</td>
</tr>
<tr>
<td>NW/RCE (RCE CORE D Y9)</td>
<td>NIH</td>
<td>$103,855</td>
<td>Goodlett</td>
<td>$519,773</td>
</tr>
<tr>
<td>Anticholinergic Med</td>
<td>Group Health Research Institute</td>
<td>$18,807</td>
<td>Gray</td>
<td>$93,491</td>
</tr>
<tr>
<td>UW-Obstetric Fetal Pharmacology RU</td>
<td>NIH NICHD</td>
<td>$515,550</td>
<td>Hebert</td>
<td>$3,250,000</td>
</tr>
<tr>
<td>pH-CD4-DDS</td>
<td>NIH</td>
<td>$586,292</td>
<td>Ho</td>
<td>$2,226,630</td>
</tr>
<tr>
<td>MIP HIV</td>
<td>NIH NIAID (U Utah subcontract)</td>
<td>$204,590</td>
<td>Ho</td>
<td>$1,061,619</td>
</tr>
<tr>
<td>Oral HIV vaccines</td>
<td>NIH</td>
<td>$277,789</td>
<td>Hu</td>
<td>$2,032,927</td>
</tr>
<tr>
<td>HIV-1 Drug Resistance</td>
<td>NIH NIAID (U Pittsburgh subcontract)</td>
<td>$181,563</td>
<td>Hu</td>
<td>$393,620</td>
</tr>
<tr>
<td>Pinter HIVRAD Prj 3</td>
<td>NIH PHRI (U of Med &amp; Dentistry of NJ subcontract)</td>
<td>$389,050</td>
<td>Hu</td>
<td>$2,307,180</td>
</tr>
<tr>
<td>Hu-IPS st-HIV-1</td>
<td>Institut Pasteur of Shanghai-Chinese Acad Sciences</td>
<td>$143,768</td>
<td>Hu</td>
<td></td>
</tr>
<tr>
<td>Modulation of receptor</td>
<td>NIH NIAID (U Mass Medical School subcontract)</td>
<td>$518,457</td>
<td>Hu</td>
<td>$2,054,979</td>
</tr>
<tr>
<td>Clade C Core</td>
<td>NIH (Dana-Farber Cancer Institute subcontract)</td>
<td>$120,652</td>
<td>Hu</td>
<td>$1,069,773</td>
</tr>
<tr>
<td>Core A – NHP Model</td>
<td>NIH NIAID (FHCRC subcontract)</td>
<td>$587,986</td>
<td>Hu</td>
<td>$3,030,628</td>
</tr>
<tr>
<td>Unmasking HIV Epitopes</td>
<td>Bill &amp; Melinda Gates Foundation</td>
<td>$5,175,945</td>
<td>Hu</td>
<td>$6,269,066</td>
</tr>
<tr>
<td>Xenobiotics</td>
<td>NIH</td>
<td>$186,219</td>
<td>Isoheranen</td>
<td>$933,664</td>
</tr>
<tr>
<td>Flu Fusion</td>
<td>NIH</td>
<td>$190,000</td>
<td>Lee</td>
<td>$950,000</td>
</tr>
<tr>
<td>Structure of HIV Env</td>
<td>NIH CFAR (U Alabama Birmingham subcontract)</td>
<td>$150,000</td>
<td>Lee</td>
<td>$207,789</td>
</tr>
<tr>
<td>Crucell Assays</td>
<td>Crucell Holland B.V.</td>
<td>$6,800</td>
<td>Lee</td>
<td></td>
</tr>
<tr>
<td>Gutman F32 Fellowship</td>
<td>NIH</td>
<td>$49,214</td>
<td>Lee</td>
<td>$101,404</td>
</tr>
<tr>
<td>Pediatric CYP2D6</td>
<td>NIH (Children’s Mercy Hosp, Kansas City subcontract)</td>
<td>$160,066</td>
<td>Lin</td>
<td>$524,287</td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>NIH</td>
<td>$250,521</td>
<td>McCune</td>
<td>$501,543</td>
</tr>
<tr>
<td>Staff assignment</td>
<td>FHCRC</td>
<td>$24,416</td>
<td>McCune</td>
<td></td>
</tr>
<tr>
<td>UNCF/Merck – Hardy</td>
<td>United Negro College Fund</td>
<td>$90,000</td>
<td>Nelson</td>
<td></td>
</tr>
<tr>
<td>Plankton</td>
<td>NSF (Georgia Inst of Tech subcontract)</td>
<td>$31,495</td>
<td>Nunn</td>
<td>$94,511</td>
</tr>
<tr>
<td>HSR and D Project – VA</td>
<td>US Dept of Veterans Affairs</td>
<td>$11,700</td>
<td>Odegard</td>
<td></td>
</tr>
<tr>
<td>Drug Metabolism Training Grant</td>
<td>NIH</td>
<td>$566,295</td>
<td>Rettie</td>
<td>$2,828,769</td>
</tr>
<tr>
<td>Drug Interactions</td>
<td>NIH</td>
<td>$937,696</td>
<td>Rettie</td>
<td>$4,672,107</td>
</tr>
<tr>
<td>Bastyr/UW Oncomycology</td>
<td>NIH</td>
<td>$18,159</td>
<td>Shen</td>
<td>$46,159</td>
</tr>
<tr>
<td>PCOR K12</td>
<td>NIH/AHRQ</td>
<td>$417,820</td>
<td>Sullivan</td>
<td>$1,160,883</td>
</tr>
<tr>
<td>Variations in Health</td>
<td>Merck and Co. Inc.</td>
<td>$148,521</td>
<td>Sullivan</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>NIH/NIGMS</td>
<td>$2,307,604</td>
<td>Thummel</td>
<td>$8,053,777</td>
</tr>
<tr>
<td>Role of CYP2J2</td>
<td>NIH</td>
<td>$222,750</td>
<td>Totah</td>
<td>$1,118,250</td>
</tr>
<tr>
<td>UW Research Affil Prg Transporters</td>
<td>AstraZeneca LP/Genentech Inc./Merck</td>
<td>$240,000</td>
<td>Unadkat</td>
<td></td>
</tr>
<tr>
<td>CANCERGEN Y2</td>
<td>NIH (FHCRC subcontract) – ARRA</td>
<td>$351,881</td>
<td>Veenstra</td>
<td></td>
</tr>
<tr>
<td>GHC SA 2</td>
<td>NIH/Group Health</td>
<td>$29,196</td>
<td>Veenstra</td>
<td></td>
</tr>
</tbody>
</table>

TOTAL: $17,454,386  TOTAL: $51,609,016

*Multiyear totals on subcontract grants are estimated based on current year funding.
Doug Black’s ability to connect with students has made him well-liked among PharmD students since he first joined the Department of Pharmacy in 1989. Black, who teaches classes in pharmacotherapeutics and infectious disease, is known for tailoring his lectures to meet each group’s needs and for his enthusiasm for his subject matter.

Like many of his faculty colleagues, Black also serves as a preceptor to future pharmacists. As part of the UW Medical Center’s Division of Infectious Diseases health care team, he mentors several pharmacy residents and PharmD students on rotation each year. Patients in this unit are facing diseases ranging from HIV/AIDS to rare infections that can have devastating symptoms. That so many students and residents finish Black’s rotation with a newfound interest in working in infectious disease units is a testament to his clinical skills.

One lesson he teaches his mentees is that it is essential to consider the specific needs and issues of each patient when determining the right combination of medications. There is no “one size fits all” in pharmacotherapy.

Just as, for Black, there is no “one size fits all” in teaching. His personal approach is one of the reasons he has received the UW’s highest teaching honor — the Distinguished Teaching Award. And it’s just one of the reasons why the PharmD program is known for innovation in education.
While he was a PharmD student, Zsolt Hepp placed nationally in two academic competitions. In 2009, he was on a student team that took grand prize in the National Community Pharmacists Association Pruitt-Schutte Business Plan Competition. In 2010, Hepp and his team placed second in the Academy of Managed Care Pharmacy’s Annual Pharmacy & Therapeutics (P&T) Competition.

As he prepared for these contests, Hepp gained a greater understanding of the complexity of the pharmacy profession and the health care system. His P&T research in particular piqued his interest. P&T focuses on formulary management — the process of approving drugs for safety and cost effectiveness and making recommendations for use and preparation. Hepp saw how much this information shapes health policy, and he decided to become involved in influencing patient outcomes at this level.

After graduating in June 2012, he took on two roles — as a pharmacist at Walgreens and an Allergan Fellow in our School’s Pharmaceutical Outcomes Research & Policy Program (PORPP). At Walgreens, Hepp is managing patients’ needs on an individual level. As a PORPP fellow, he is evaluating health-related outcomes for medications on a larger scale. At present, he is examining resource-use patterns in migraine patients using prophylactic medications.

When he enrolled at the UW, Hepp didn’t know he’d become interested in so many different aspects of patient care. But that’s what the School of Pharmacy is about — creating diverse opportunities and letting students like Hepp find their passion and thrive.

PharmD candidate Laura Hart, ’14, spent three years volunteering at a long-term care center pharmacy prior to pharmacy school. While there, she saw firsthand the important role pharmacists play in improving the health of older adults. As someone close to her own grandparents, she loved working with this population of people.

Today, the third-generation UW pharmacy student contributes widely to the School’s efforts to advocate for older populations. She is president of the UW student chapter of the American Society of Consultant Pharmacists (ASCP) — a geriatric pharmacy organization. Her work with ASCP has included organizing and participating in medication reviews, fall-prevention programs and osteoporosis-prevention workshops.

Hart is pursuing the Plein Certificate in Geriatric Pharmacy, and she is a Plein Fellow in Geriatrics. As a fellow, she recently started a research project with UW Pharmacy Cares, the School’s consulting pharmacy program. She and faculty members Karan Dawson and Susan Lakey are working with two Era Living Retirement Community sites to look at medication-related problems and to assess resident, family and staff perceptions of consulting pharmacy services.

Hart is one of many UW PharmD students who are highly involved in outreach, research and leadership activities. What’s more, her fellow students are engaged in projects supporting many populations and public health issues. In the pharmacy field, after all, there are countless ways to make a difference. For Hart, this means a future career serving the complex health needs of a generation close to her heart.
Each year, 1.7 million people in the United States sustain a traumatic brain injury. Although numerous clinical studies have tried using single drug treatments for people with brain injuries, the results have been overwhelmingly disappointing. Gail Anderson, professor of pharmacy and adjunct professor of pharmaceutics and neurosurgery, is in search of a more successful treatment method. Her current research, funded by a $2.5 million NIH grant, seeks to identify combinations of medications that could prevent long-term health issues for brain-injured patients. Some of these long-term issues include epilepsy and residual physical, cognitive, emotional and behavioral impairment.

Anderson knows that daily life can change significantly for patients diagnosed with epilepsy. With this in mind, she has been a patient advocate, community volunteer and professional advisory board member of the Epilepsy Foundation Northwest for more than 20 years. She also precepts pharmacy students at the UW Regional Epilepsy Center at Harborview Medical Center — helping them provide the best care possible to patients in the clinic and at the bedside.

A UW alumna (BS in pharmacy, MS in pharmacy practice, PhD in pharmaceutics), Anderson received the School’s 2010 Distinguished Alumna Award for her research, teaching and community involvement. It is one of many career honors she has received. While Anderson appreciates such accolades, what she especially appreciates is knowing that her research could one day help people seeking hope after surviving a traumatic injury.
Pharmaceutical Outcomes Research & Policy Program (PORPP) graduate student Amy Cizik spent last summer in Dar Es Salaam, Tanzania piloting a mobile phone application that enters surgical follow-up data. Cizik sought to determine whether surgeons at the Muhimbili Orthopaedic Institute could more easily enter patients’ post-surgery progress with a smart phone data and photo application than with traditional data entry methods.

Andy Stergachis, PORPP adjunct professor and UW professor of global health, guided Cizik in her proposal for funding and served as her project mentor. The funding came from the UW Thomas Francis, Jr., Global Health Fellowship Program. In addition, Cizik collaborated with SIGN Fracture Care International, a humanitarian organization that provides orthopaedic treatment to people in developing countries.

What Cizik ultimately discovered during her time in Tanzania was that few people who receive fracture care at the Institute actually return for follow-up. They don’t have the means to get back to the clinic to meet with a physician. Cizik, therefore, will continue working with SIGN to assess better methods for patient follow-up. Ultimately, she hopes to help SIGN track patients’ outcomes and to help SIGN’s patients worldwide get the appropriate follow-up care in their recovery process.

Cizik enrolled in PORPP because of its focus on improving health care decisions for patients and decision makers. With a background in public health and orthopaedics research, she wanted to research the clinical and economic effects of orthopaedic devices in patient populations.

In the future, she hopes to collaborate with orthopaedic surgeons to study cost and outcomes of orthopaedic interventions or to help surgeons in other countries conduct similar research. No matter how this takes shape, she will have an international network of support as an alumna of PORPP.

Cizik, who went to Tanzania as a UW Thomas Francis, Jr., Global Health Fellow, enrolled in PORPP because of its focus on improving health care decisions for patients and decision makers.
More than a decade ago, Professor of Pharmaceutics Jashvant Unadkat began studying how drug transporters affect the disposition, efficacy and toxicity of drugs used to treat diseases such as hepatitis C and AIDS. Transporters are membrane proteins that help the body absorb, distribute, metabolize and excrete drugs. Given the complexity of transporters, the variability of human genetics, and the sheer volume of transporters in the human body, the collective scientific knowledge about transporters has long contained many gaps. Unadkat seeks to change that.

In 2012, he launched the UW Research Affiliates Program on Transporters (UWRAPT), a partnership between the School of Pharmacy and AstraZeneca, Genentech and Merck. The UW Center for Commercialization and Office of Sponsored Programs helped make this undertaking possible.

Through UWRAPT, researchers from the four institutions are collaborating on nonproprietary research to enhance knowledge about the types and amount of transporters expressed in human tissues. This kind of academic-industry collaboration on nonexclusive research is rare. And it has exciting implications for other potential future partnerships that our School could launch.

Unadkat and UWRAPT lead scientist Bhagwat Prasad hope UWRAPT’s research will advance the collective knowledge about how the body processes medicines. They want to help scientists better predict the fate of new drugs early in development. In turn, this will help health care providers prevent drug interactions and understand how genetics affect the way individuals process medications.

“This kind of academic-industry collaboration on nonexclusive research is rare. And it has exciting implications for other potential future partnerships that our School could launch.”
A Continued Legacy of Innovation

Our School is continually finding ways to innovate education, research and outreach. In fact, we’re leading the way in these endeavors. The following are some of the new programs we have launched in the past five years alone:

• Analytical Biopharmacy Core, in partnership with the UW Department of Bioengineering
• Biomedical Regulatory Affairs Master of Science
• Certificate in Health Economics and Outcomes Research
• Graduate Certificate in Comparative Effectiveness Research
• Northwest-Alaska Pharmacogenomics Research Network, in partnership with several tribes, foundations and universities
• Pharmacological Sciences Summer Diversity Research Program
• UW Global Medicines, in partnership with the UW Department of Global Health
• UW Pharmacy Cares Consulting Pharmacy
• UW Research Affiliate Program on Transporters, in partnership with AstraZeneca, Genentech and Merck

Opening Doors for Young Researchers and Scientists

Professor of Medicinal Chemistry Carlos Enrique Catalano has devoted his career to understanding how viruses work — specifically how they put themselves together in an infected cell. Current studies in his lab focus on HIV and on bacteriophage lambda, a virus that looks and behaves like the herpes viruses. By enhancing scientific knowledge about the formation of these viruses, Catalano’s research could make it easier for researchers to design specific antiviral drugs and vaccines.

Catalano is also devoted to mentoring young people from diverse backgrounds. As faculty adviser to the award-winning UW chapter of the Society for the Advancement of Chicanos and Native Americans in Science, Catalano works with an enthusiastic group of undergraduate and graduate students engaged in scientific research. These students themselves have developed outreach programs for Latino and Native American high schools.

Like many other faculty members, he also offers undergraduates the chance to work in his lab. Students come to the Catalano Lab from programs such as the Amgen Scholars Program, the UW School of Pharmacy’s Pharmacological Sciences Summer Diversity Program, and the UW’s Post-Baccalaureate Research Education Program (PREP), funded by NIH. Catalano helped create the Diversity Program and he serves as co-PI for PREP.

Catalano enjoys trying to instill a love of science in young people. Who knows? One day, one of those young people might work on the cure for a virus studied in the Catalano Lab.

Carlos Catalano is known throughout the scientific community for his wide-ranging efforts to encourage young people to take an interest in the sciences.
We are so grateful to our volunteers and donors for their time, energy and financial contributions. Their support is critical to our efforts to educate first-rate pharmacists, develop scientific leaders and serve the community. In these pages, we present the names of the companies and individuals that made gifts to our School at the Dean’s Club Level and above, and those that gave donations to student events in fiscal year 2012 (July 1, 2011 to June 30, 2012). We also present the names of our advisory board members from fiscal year 2012.

While these are our most prominent supporters, there are countless more individuals and companies working behind the scenes to support our students, faculty and School in so many ways. We are indebted to every single one of you.

Our Donors

CORPORATIONS AND FOUNDATIONS

$25,000+

Allergan Inc.
Amgen
Bayer AG
ERA Living
Bill & Melinda Gates Foundation
Genentech
Kelley-Ross Pharmacy
McKesson Corporation
Merck & Co. Inc.
Pfizer Inc.
PhRMA Foundation
Public Health Research Institute
United Negro College Fund

Rite Aid Corporation
Safeway District Management
The Bartell Drug Company
WA State Pharmacy Foundation
Walter & Hazel Hinman Fdtn.

LESS THAN $2,500

Abbott Fund
Albertson’s Inc.
Aqua Verde Cafe Paddle Club
Asia Gifts & Aquarium
Beal’s Compounding Pharmacy
Bergman Luggage Company Inc.
Bioscrip Pharmacy
Bob Johnson’s Pharmacy
The Boeing Company

Bonck Family Trust
Bristol-Myers Squibb Foundation
Career Staff Rx
Central WA Hospital Pharmacy
Chinook Pharmacy Inc.
Columbia Valley Com. Health

Com. Health Ctr. of Snohomish
Community Pharmacy Scotland
Dimitriou’s Jazz Alley
Dow AgroSciences LLC
Evergreen Hospital Med Ctr.
Evergreen Senior Health Specialist
Experience Music Project
Fdttn. for Managed Care Pharmacy
Fred Meyer
Garage
Garfield Medical Square Pharmacy
Genelex
Greater Everett Community Fdtn.
Green Mountain Coffee Roasters
Harrison Medical Center
HealthPoint
Island Hospital Anacortes

A proud tradition continues:
Our School is once again ranked No. 1 among all UW schools in terms of percentage of alumni giving!

Newly Created School of Pharmacy Funds 2012

• Andjelkovic Connell Endowed Student Support Fund
• Doug Black Endowed Fund
• Higashi Family PORPP Endowed Student Fellowship Fund
• Kelley-Ross Faculty Fellowship
• Dennis Lam Memorial Fund
• Stergachis Family Endowed PORPP Directorship

$10,000 - $24,999

GlaxoSmithKline
The Kroger Co.
Walgreens

$2,500 - $9,999

AcademyHealth
American Pharmacists Association
Bi-Mart
CVS Caremark
Eli Lilly & Co. Foundation
GE Foundation
Genentech Inc.
John Wiley & Sons Inc.
Kelley-Ross Pharmacy Inc.
Lincoln Pharmacy
Morgan Stanley/SmithBarney

continued on page 11
Remodeled Bracken Center Unveiled

In fall quarter 2012, the newly remodeled L.D. & Jim Bracken Pharmacy Learning Center, our PharmD student learning lab, opened! It features upgrades to the center’s integrated learning areas, which include a sterile products preparation room, patient-counseling areas and a retail space. In addition, the beautiful new lab now has advanced QS1 software and more advanced pharmacy learning technology.

This remodel was made possible by the Bracken Family, CVS Pharmacy, Kelley-Ross Pharmacy, McKesson Inc. and Walgreens.

(continued on page 12)
Kevin Hiroo
Rodney Ho & Lily Hwang-Ho
Richard & Janet Hunter
Al & Carolyln James
Bradley Kerr & Caroline Lee
Kevin Koch & Kathy Maloney
Stephen & Kathy Kushner
Mark Holodniy & RoseAnn Kushner
Craig & Sally Kvaam
Michael & Tammy Lafferty
Virginia Leland
Donavon & Nicole McConn
David Nelson
Patrick & Missy O'Donnell
Richard & Jane Ramsey
Brian Seiki
Kenneth & Peggy Thummel
Chris & Gail Whitley
Larry & Margaret Wienenks
Donald & Arda Williams
Bradley Wong
Mingshe Zhu

DEAN’S CLUB
Kimberly Adkison
Arnold & Gail Anderson
Richard & Teresa Austin
Ronald & Kathleen Beil
Cynthia Bishop
Kari & Adam Brothers
Cindy Bueler
Sonja Carlson & Bobby Kishore
Judith & Barry Christensen
Bonnie & Walter Davison
James & Karan Dawson
Beth Devine
Leslie Dickmann
Donald & Donna Dockter
Donald & Anne Downing
Gregory Edmiston & Debra Leith
Jon Eisenberg & Soraya Madani
William & Sharon Fassett
Andrew & Claire Forster
Vivian & Roel Ganiron
Mark & Sissi Grillo
Shuko Hara
Thomas Hazlet
Kirk Henne
Nina Hill
Vivian & Jeffrey Hiroo
Peng Hsiao
Shiu-Lok Hu
Lorraine Humm
Paul & Mary Kuehn
Joseph & Yue Lam
Sze Lau
Rene & Beloria Levy
Richard & Margaret Marshall
Anne Mock
Michael Mohutsky
Kellie Nakamura
David & Peggy Odegard
Larry & Ellen Oliver
Marla & Patrick Osinski
Guy Padbury
Ruth & Patrick Parker
Kevin Pasquali
Gregory & Gloria Pollock
C. Rene & David Porubek

“Because of the support of people like you, I was able to achieve my dream and attend this university. I hope my experience at the UW will lead to opportunities that will help me contribute to a wide variety of populations in my career.” PAIGE MATHEW, ’16, SCHOLARSHIP RECIPIENT
James & Patricia Ramseth
Shelby & Steve Reed
James & Diann Robbers
Henry Sasame
Harry Schnepf II & Cameron Fosterling
Donald & Sharon Shaw
Shabir & Salma Somani

Allan Rettie & Shannon Stewart
SuAnn Stone
Bettie Tomchak
Clyde & Sherrelle Walker
Joann Warren
Kelli Watari

YOUNG ALUMNI
DEAN’S CLUB
Jonathan & Christina Campbell
Aaron Chin
Stephanie Decker & George Guenther

Every effort has been made to represent the names of our donors at the Dean’s Club level and above in fiscal year 2012 accurately. We apologize for any errors or omissions. For a full list of donors to the School, visit sop.washington.edu and view the Fall 2012 alumni magazine, Dawg Scripts.

Our Board Members

CORPORATE ADVISORY BOARD
(Organizations with Member Representatives)
Abbott Laboratories
Allergan Inc.
Amgen Inc.
Astellas U.S. Inc.
AstraZeneca
Bayer Healthcare
Bend Research Inc.
Biogen Idec
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Celgene Corporation
Covance
dwm Consulting LLC
Eli Lilly & Co.
En Vivo
GE Healthcare
Genentech Inc.
GlaxoSmithKline
Hoffman-La Roche
Ironwood Pharmaceuticals
Janssen Alzheimer Immunotherapy
Johnson & Johnson
Lilly Research Labs
McKesson Corp.
Medtronic
Merck
Mitsubishi Tanabe
Novartis
Omeros Corp.
Pfizer Inc.
Premera Blue Cross
Sanofi-Aventis
SAR Safety Assessment
Seattle Genetics
Takeda Pharmaceuticals International
Theravance Inc.
Vertex Pharmaceuticals

PHARMACY PRACTICE ADVISORY BOARD
Carol Carnahan, ’80, Bartell Drug Co.
Collin Conway, ’05, Group Health
Daiana Huyen, Walgreens
Al Linggi, ’71, McKesson Corp.
Ryan Oftebro, ’03, Kelley-Ross Pharmacy
Chuck Paulsen, Quality Food Centers
Jeff Rochon, ’99, WSPA
Steve Singer, ’81, Bellegrove Pharmacy
Shabir Somani, UW Medicine
Susan Teil Boyer, ’72, American Society of Health-System Pharmacists
David West, ’79, Swedish Hospital
Jennifer Wilson-Norton, ‘93, The Evergreen Clinic

PHARMACY ALUMNI ASSOCIATION BOARD OF DIRECTORS
President:
Jennifer Glasco, ’09, The Polyclinic
Immediate Past-President:
Jenny Arnold, ’06, Washington State Pharmacy Association (WSPA)
Past Presidents:
Suzanne Lee, ’88, Northwest Hospital, and Ben Michaels, ’97, St. Francis Hospital
Member at Large:
Judi Mar-Burbidge, ’82, ’00, Seattle Veterans Administration
Katterman Chair:
Don Downing, ’75, UW School of Pharmacy
WSPA Liaison:
Jeff Rochon, ’99, WSPA

At left is UW Professor of Epidemiology and Global Health and Adjunct Professor of Pharmacy Andy Stergachis. To his right are Stergachis Family Endowed PORPP Director and Professor Sean Sullivan, School of Pharmacy Distinguished Alumnus Award Recipient Ryan Hansen, PharmD, ’03, PhD, ’12, and Washington State Pharmacy Foundation President John Oftebro.


Chan LN. To Hold (Enteral Feeding) or Not to Hold: That IS the Question; A Commentary and Tutorial. Practical Gastroent 2012.


Endsley AN, Ho RJY. Design and characterization of novel peptide coated lipid nanoparticles for specific anti-HIV drug delivery to HIV host cells. AAPS J 2012.


Hansten P, Horn JR. The Top 100
Drug Interactions: A Guide to Patient
Management. Freeland, WA: H&H
Publications; 2012.

Harrelson JP, Stamper BD, Chapman
JD, Goodlett DR, Nelson SD. Covalent
Modification and Time-Dependent Inhibition
of Human CYP2E1 by the Meta Isomer of
Acetaminophen. Drug Metab Dispos 2012.

Hebert MF. Impact of Pregnancy on Maternal
Pharmacokinetics of Medications (chapter).
Clinical Pharmacology During Pregnancy.
Mattison D).

Ho HT, A Dahlin, Wang J. Expression profiling of solute carrier gene families at the blood-


Horn JR, Hansten PD. Metoclopramide and Dyskinesia. Pharm Times 2012.


Kirby BJ, Collier AC, Kharasch ED, Dext V, Desai P, Whittington D, Thummel KE, Unadkat JD. Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Inhibition of Cytochrome P450 1A2, 2B6 and 2C9 by Ritonavir or Nelfinavir. Drug Metab Dispos 2011.


Lam AL, Odegard PS, Gardner JS. School of Pharmacy-based medication therapy management program: Development and initial experience. J APHA 2012.


Ni ZL, Bikadi Z, Shuster DL, Zhao CS, Rosenberg MF, Mao Q. Identification of proline residues in or near transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochem 2011.


In the past few years, our faculty members have been interviewed for stories in the Associated Press, New York Times, Huffington Post, Seattle Times and Pacific Northwest Magazine, as well as for stories on KUOW radio and KOMO4 TV, among others.
EXCELLENCE AT THE SCHOOL OF PHARMACY 2013

Connect With Us
sop.washington.edu
www.facebook.com/uwsop
www.linkedin.com
(University of Washington School of Pharmacy “Pharmacy Practice Alumni and Friends” group or “Graduate Programs Alumni and Friends” group)

Credits
EDITOR AND WRITER: Melinda Young
DESIGNER: Karin Mellskog, UW Creative Communications
PROOFREADER: Sharon Ernst, We Know Words
CONTRIBUTORS: Thomas Baillie, Jessica Brase, Ray Brooks, Sarah Egan, Claire Forster, Julie Hill, Christene James, Jeanine Kanov, Dima Long, Maura Murphy, Tracie Zeigler
PHOTOGRAPHERS: Matt Hagen Photography, Karen Heath Photography, Michael Naiman of Team Photogenic
ADDITIONAL PHOTO CREDITS: iStock, ThinkStock, UW Marketing
Special thanks to UW Creative Communications, Litho Craft, and the many faculty, staff, students and work study students who contributed photos, information and general feedback to this report.

For general inquiries, email pharminf@uw.edu

For admissions info, visit sop.washington.edu/school-of-pharmacy/degree-programs
To make a gift, visit sop.washington.edu/support

sop.washington.edu
“Part of our core mission is to help ensure the safe, rational and cost-effective use of medicines and medical products in human populations. What a worthwhile goal this is. Better treatments lead to improved health outcomes. And that can **open doors** to a world of better health.”  

DEAN THOMAS BAILLIE